These are the stocks posting the largest moves before the bell Monday.Market Insiderread more
The brokerage says that the globe is "one step away" from recession as the world's two largest economies head to the G-20 summit.Marketsread more
As candidates from Elizabeth Warren and Bernie Sanders to John Delaney jockey for position in the 2020 Democratic primary, business issues will come up in the first debates.2020 Electionsread more
Trump says he would impose additional sanctions against Iran in a bid to prevent the country obtaining nuclear weapons.World Politicsread more
The major indexes have stretched to all-time highs and are riding one of their best first halves in decades.Trading Nationread more
Tensions between the U.S. and Iran will likely escalate in the near future, a former adviser to the Iranian government said on Monday.Energyread more
Millennial stocks are looking fly this month, and one name could be on the verge of exploding in the next year.Trading Nationread more
Chinese vice commerce minister said Monday that Beijing would like the U.S. to cancel "inappropriate" actions against Chinese companies.China Economyread more
Eldorado Resorts has agreed to merge with Caesars Entertainment in a cash and stock deal that values its peer at about $17.3 billion including debt.Casinos and Gamingread more
A decisive win for Turkey's main opposition party in a re-run of a mayoral election in Istanbul has prompted hopes for reforms.Europe Politicsread more
Sixteen Asia Pacific countries have been negotiating the Regional Comprehensive Economic Partnership since 2013, with India's reluctance to open up its markets a major...Asia Economyread more
Former FDA commissioner Robert Califf is in talks with Alphabet's life sciences arm Verily for a leadership role, according to several people familiar with the matter. (Update: Califf announced the news on Verily's blog on Wednesday.)
Califf has been spotted at the company's South San Francisco offices, said one person. The details of the position are still being worked out, and the talks could fall through, but Califf, a legendary cardiologist, is expected to take a joint role at Stanford and Verily.
Califf would join shortly after the launch of Verily's baseline study, a well-funded effort headed up by fellow cardiologist Jessica Mega to study human health by tracking 10,000 people over at least 4 years.
Both Stanford Medicine and Duke University, where Califf is currently on leave as a tenured cardiologist, have been named as partners in that study.
The appointment of Califf would be a big win for Verily, and couldn't come at a better time. The company just lost its top academic, former National Institute of Mental Health chief Tom Insel. Insel was the latest in a series of high-profile departures from Alphabet, Google's parent company, which also includes Nest's Tony Fadell, GV's Bill Maris, and Google Fiber chief Craig Barratt.
Califf was nominated for the FDA role by President Barack Obama and stepped down in January of this year, a standard procedure with a new administration. Shortly after stepping down, he spoke out in an interview about the antiquated ways in which companies collect medical data to test new drugs and medical devices. He suggested that clinical trials should look more like A/B comparison tests routinely done by tech companies, such as Google.
It's not typical for health agency chiefs to join technology companies, but it might increasingly be an option as Silicon Valley starts moving into regulated industries. Verily works closely with life sciences companies — including Dexcom,
Watch: Dr. Califf offers advice to his successor at FDA